These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30339245)

  • 21. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The assessment of HER2 status in breast cancer: the past, the present, and the future.
    Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
    Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits.
    Pekar G; Kasselaki I; Pekar-Lukacs A; Dekany C; Hellberg D; Tot T
    Histopathology; 2019 Jan; 74(2):300-310. PubMed ID: 30113715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice.
    Liao CC; Bakoglu N; Cesmecioglu E; Hanna M; Pareja F; Wen HY; D'Alfonso TM; Brogi E; Yagi Y; Ross DS
    Pathol Oncol Res; 2024; 30():1611826. PubMed ID: 39267995
    [No Abstract]   [Full Text] [Related]  

  • 25. Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.
    Sandén E; Khazaei S; Tryggvadottir H; Borgquist S; Isaksson K; Jirström K; Jernström H
    Virchows Arch; 2020 Aug; 477(2):317-320. PubMed ID: 32080761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer.
    Katayama A; Miligy IM; Shiino S; Toss MS; Eldib K; Kurozumi S; Quinn CM; Badr N; Murray C; Provenzano E; Callagy G; Martyn C; Millican-Slater R; Purdie C; Purnell D; Pinder SE; Oyama T; Shaaban AM; Ellis I; Lee AHS; Rakha EA
    Mod Pathol; 2021 Jul; 34(7):1271-1281. PubMed ID: 33526875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer.
    Grant KA; Pienaar FM; Brundyn K; Swart G; Gericke GS; Myburgh EJ; Wright CA; Apffelstaedt JP; Kotze MJ
    Breast; 2015 Apr; 24(2):137-42. PubMed ID: 25586984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
    Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
    BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
    Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
    J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study.
    Hicks DG; Buscaglia B; Goda H; McMahon L; Natori T; Turner B; Soukiazian A; Okada H; Nakano Y
    BMC Cancer; 2018 Dec; 18(1):1266. PubMed ID: 30563489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH.
    Jensen SG; Thomas PE; Christensen IJ; Balslev E; Hansen A; Høgdall E
    APMIS; 2020 Nov; 128(11):573-582. PubMed ID: 32860265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
    Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
    Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of a Dual (Immunohistochemistry and Fluorescence In Situ Hybridization) HER2/neu Testing Strategy on Invasive Breast Cancers.
    Hariri N; Zare S; Murphy J; Fadare O
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):42-48. PubMed ID: 32205742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
    Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
    Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
    Curado M; Caramelo AS; Eloy C; Polónia A
    Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
    Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
    Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 immunohistochemical scores provide prognostic information for patients with HER2-type invasive breast cancer.
    Tsai YF; Tseng LM; Lien PJ; Hsu CY; Lin YS; King KL; Wang YL; Chao TC; Liu CY; Chiu JH; Yang MH
    Histopathology; 2019 Mar; 74(4):578-586. PubMed ID: 30515868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Divisional role of quantitative HER2 testing in breast cancer.
    Yamamoto-Ibusuki M; Yamamoto Y; Fu P; Yamamoto S; Fujiwara S; Honda Y; Iyama K; Iwase H
    Breast Cancer; 2015 Mar; 22(2):161-71. PubMed ID: 23604955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.